<?xml version="1.0" ?>
<document id="45d3b6128146d7df335e96fb8257644f0a5fca14">
  <chunk id="45d3b6128146d7df335e96fb8257644f0a5fca14.c0" text="Human Respiratory Syncytial Virus NS 1 Targets TRIM25 to Suppress RIG-I Ubiquitination and Subsequent RIG-I-Mediated Antiviral Signaling">
    <entity charOffset="117-126" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c0.e0" ontology_id="CHEBI_22587" text="Antiviral" type="chemical"/>
  </chunk>
  <chunk id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1" text="Respiratory syncytial virus (RSV) causes severe acute lower respiratory tract disease. Retinoic acid-inducible gene-I (RIG-I) serves as an innate immune sensor and triggers antiviral responses upon recognizing viral infections including RSV. Since tripartite motif-containing protein 25 (TRIM25)-mediated K63-polyubiquitination is crucial for RIG-I activation, several viruses target initial RIG-I activation through ubiquitination. RSV NS1 and NS2 have been shown to interfere with RIG-I-mediated antiviral signaling. In this study, we explored the possibility that NS1 suppresses RIG-I-mediated antiviral signaling by targeting TRIM25. Ubiquitination of ectopically expressed RIG-I-2Cards domain was decreased by RSV infection, indicating that RSV possesses ability to inhibit TRIM25-mediated RIG-I ubiquitination. Similarly, ectopic expression of NS1 sufficiently suppressed TRIM25-mediated RIG-I ubiquitination. Furthermore, interaction between NS1 and TRIM25 was detected by a co-immunoprecipitation assay. Further biochemical assays showed that the SPRY domain of TRIM25, which is responsible for interaction with RIG-I, interacted sufficiently with NS1. Suppression of RIG-I ubiquitination by NS1 resulted in decreased interaction between RIG-I and its downstream molecule, MAVS. The suppressive effect of NS1 on RIG-I signaling could be abrogated by overexpression of TRIM25. Collectively, this study suggests that RSV NS1 interacts with TRIM25 and interferes with RIG-I ubiquitination to suppress type-I interferon signaling.">
    <entity charOffset="54-85" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e0" ontology_id="DOID_0050161" text="lower respiratory tract disease" type="disease"/>
    <entity charOffset="173-182" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e1" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="276-283" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e2" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="498-507" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e3" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="597-606" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e4" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="1513-1523" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e5" ontology_id="CHEBI_52999" text="interferon" type="chemical"/>
    <pair e1="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e0" e2="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e1" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.p0" relation="true"/>
    <pair e1="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e0" e2="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e2" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.p1" relation="true"/>
    <pair e1="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e0" e2="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e3" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.p2" relation="true"/>
    <pair e1="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e0" e2="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e4" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.p3" relation="true"/>
    <pair e1="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e0" e2="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.e5" id="45d3b6128146d7df335e96fb8257644f0a5fca14.c1.p4" relation="true"/>
  </chunk>
</document>
